Irbesartan Tetrafarma (Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release. This results in blood vessel relaxation, reduced sodium and water retention, lower blood pressure, and decreased progression of kidney damage in diabetes.

The appropriate dose of Irbesartan Tetrafarma is determined by a qualified prescriber based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosing instructions provided by their healthcare professional and not adjust the dose on their own.

Irbesartan is generally not recommended during pregnancy because it may affect fetal development. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatments with their healthcare provider to ensure safety for both mother and child.

To order Irbesartan Tetrafarma, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Irbesartan belongs to the ARB class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough. Compared with calcium‑channel blockers or diuretics, ARBs provide a distinct mechanism by blocking angiotensin II receptors, making them useful when other classes are not tolerated.

Irbesartan Tetrafarma should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight or extreme heat to maintain its stability and potency.

Irbesartan Tetrafarma is taken orally, usually with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a prescriber.

The most serious risks include angioedema (swelling of the face, lips, tongue, or airway), severe hypotension, acute renal failure, and hyperkalemia (elevated potassium levels). Patients should seek immediate medical attention if they experience symptoms such as swelling, faintness, or rapid changes in kidney function.

Irbesartan Tetrafarma should be avoided in individuals with known hypersensitivity to Irbesartan or any ARB component, those with severe hepatic impairment, and patients who are pregnant unless the benefits outweigh the risks. It should also be used with caution in patients with existing kidney disease or high potassium levels.